China NMPA Drug Inspection - Anhui Bozhou Haomen Pharmaceutical Factory (Powdered Herbs/Granules) - Tetrapanax papyriferus

On September 26, 2018, the Henan Provincial Food and Drug Administration announced the findings of drug inspections that identified four batches of substandard drugs from three manufacturers. Anhui Bozhou Haomen Pharmaceutical Pieces (Granules) Factory was cited for two products: Magnolia officinalis (batch 0161118R) had substandard content, and Tetrapanax papyriferus (batch 0170215R) showed a substandard appearance. Henan Baiyuankang Pharmaceutical Co., Ltd.'s Psoralea corylifolia (batch 160401) failed due to substandard content. Shangqiu Jinma Pharmaceutical Co., Ltd.'s Muxiang Shunqi Pills (batch 16041221) exhibited substandard content uniformity. These violations were determined against the standards of the Chinese Pharmacopoeia 2015 Edition, Part I. In response, the Henan Provincial Food and Drug Administration instructed local regulatory bodies to implement immediate risk control measures, including sealing, seizing, and suspending sales of the affected drugs. Additionally, thorough investigations and legal enforcement actions against the implicated companies were mandated.